Frequently Asked Questions about Eli Lilly and Company (LLY)

Name: Eli Lilly and Company (LLY) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Eli Lilly and Company (LLY) do?

Accepted Answer

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a...

Question 2

Is Eli Lilly and Company (LLY) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of LLY reveals an Altman Z-Score of 7.97 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($65.18B most recent), help investors decide if LLY fits their risk profile.

Question 3

What is the current P/E ratio for LLY?

Accepted Answer

As of the latest trading session, Eli Lilly and Company (LLY) has a trailing P/E ratio of 40.32.

Question 4

Who is the CEO of Eli Lilly and Company?

Accepted Answer

The current Chief Executive Officer of Eli Lilly and Company is David A. Ricks.

Question 5

What was LLY's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Eli Lilly and Company reported annual revenues of $65.18B (2025), $45.04B (2024), $34.12B (2023), $28.54B (2022), $28.32B (2021) respectively.

Question 6

Does LLY pay a dividend?

Accepted Answer

Eli Lilly and Company currently pays a dividend to its shareholders, with a trailing dividend yield of 0.67%.

Question 7

How much debt and cash flow does LLY have?

Accepted Answer

In its latest reporting period, Eli Lilly and Company generated $8.97B in Free Cash Flow against a total debt load of $42.50B.

Question 8

What is the Price-to-Book (P/B) ratio of Eli Lilly and Company?

Accepted Answer

The Price-to-Book (P/B) ratio for Eli Lilly and Company (LLY) is currently 31.36.

Question 9

What is the Price-to-Sales (P/S) ratio of LLY?

Accepted Answer

Based on trailing twelve-month data, Eli Lilly and Company (LLY) trades at a Price-to-Sales (P/S) ratio of 13.43.

Question 10

What is Eli Lilly and Company's Return on Equity (ROE)?

Accepted Answer

Eli Lilly and Company (LLY) has a Return on Equity (ROE) of 97.85%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	65.2B	54.6B	29.7B	20.6B	23.00
2024-12	45B	36.6B	17.5B	10.6B	11.76
2023-12	34.1B	27B	10.8B	5.2B	5.83
2022-12	28.5B	21.9B	8.7B	6.2B	6.57
2021-12	28.3B	21B	7.9B	5.6B	5.85

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	65.2B	54.6B	29.7B	20.6B	23.00
2024-12	45B	36.6B	17.5B	10.6B	11.76
2023-12	34.1B	27B	10.8B	5.2B	5.83
2022-12	28.5B	21.9B	8.7B	6.2B	6.57
2021-12	28.3B	21B	7.9B	5.6B	5.85